Quantgene, which was founded in 2015, has been developing a form of genomic testing known as liquid biopsy that analyzes genetic mutations in blood samples to detect cancer and other diseases.
Vikor Scientific, which is headquartered in a life sciences campus near the Medical University of South Carolina, has a certified lab that screens for molecular pathogens on behalf of medical providers.
Under the marketing partnership, Vikor will tap its medical provider customer base to help commercialize Quantgene’s liquid biopsy genomic test platform, which it calls Serenity.
“We are first-to-market in combining liquid biopsy cancer detection with whole exome sequencing and advanced medical intelligence,” Jo Bhakdi, Quantgene’s founder and chief executive, said in the announcement. “We hope to unlock a new era in medicine in which trained physicians can detect multiple cancers at early stages in the blood with single molecule precision.”
For Vikor, its investment in Quantgene and the marketing partnership give it access to what it hopes proves a powerful new diagnostic tool.
“The platform built by the Quantgene team is revolutionary and certain to accelerate the speed at which we diagnose and treat patients for cancer,” Scotty Branch, co-founder of Vikor Scientific, said in the announcement.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Quantgene Teams With Cancer Therapy Guidance Company
- Local Teams Develop Less Invasive Cancer Technologies
- Quantgene Dials in Tests
- Cancer Awareness: Early Detection Legislation Introduced in Senate
- Investors Wonder What Comes Next for Fulgent Genetics
- UCLA Receives $5M Federal Grant to Study Early Lung Cancer Detection
- UCLA Cancer Researchers Land $3 Million Grant
- Health care hospitals